Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: Preferential involvement of the NR2B rather than NR2A subunit

Behavioural Pharmacology

Volumn 14, Issue 5-6, 2003, Pages 477-487

  Chaperon, F ^a   Muller W ^a   Auberson, Y P ^a   Tricklebank, M D ^a,b   Neijt, H C ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Drug discrimination; Locomotor activity; NMDA receptor; Prepulse inhibition; Rat

Indexed keywords

4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; [[1 (4 BROMOPHENYL)ETHYLAMINO] 2,3 DIOXO 1,2,3,4 TETRAHYDROQUINOXALIN 5 YLMETHYL]PHOSPHONIC ACID; ALPHA (4 HYDROXYPHENYL) BETA METHYL 4 (PHENYLMETHYL) 1 PIPERIDINE PROPANOL OXALATE; ALPHA AMINO 2' CHLORO 5 (PHOSPHONOMETHYL) 1,1' BIPHENYL 3 PROPANOIC ACID; ALPHA AMINO 5 (PHOSPHONOMETHYL)[1,1' BIPHENYL] 3 PROPANOIC ACID; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NVP AAM 077; PHENCYCLIDINE; PROTEIN SUBUNIT; SDZ 220 581; SDZ 221 653; SDZ 221653; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; CONFERENCE PAPER; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG EFFECT; HYPERACTIVITY; INSTRUMENTAL CONDITIONING; LOCOMOTION; MALE; NONHUMAN; PREPULSE INHIBITION; RAT; SENSORIMOTOR CORTEX;

ANIMALS; CONDITIONING, OPERANT; DISCRIMINATION LEARNING; EXCITATORY AMINO ACID ANTAGONISTS; HALLUCINOGENS; LOCOMOTION; MALE; PHENCYCLIDINE; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0141757281     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (63)

1. Arvanov VL, Wang RY (1997). Clozapine and haloperidol modulate N-Methyl-D-aspartate and non-N-Methyl-D-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234.
2. Asztely F, Gustafsson B (1996). Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Mol Neurobiol 12:1-11.
3. Auberson YP, Allgeier H, Bischoff S, Lingenhoehl K, Moretti R, Schmutz M (2002). 5-Phosphonomethylquinoxalinediones as competitive NMDA receptor antagonists with a preference for the human 1A/2A, rather than 1A/2B receptor composition. Bioorg Med Chem Lett 12:107-110.
4. 2B receptors expressed in Xenopus oocytes. Neurosci Lett 223:133-136.
5. Bakshi VP, Geyer MA (1995). Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 122:198-201.
6. Bakshi VP, Tricklebank MD, Neijt HC, Lehman-Masten V, Geyer MA (1999). Disruption of prepulse inhibition and increase in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats. J Pharmacol Exp Ther 288:643-652.
7. Balster RL, Nicholson KL, Sanger DJ (1994). Evaluation of the reinforcing effects of eliprodil in rhesus monkeys and its discriminative stimulus effects in rats. Drug Alcohol Depend 35:211-216.
8. Balster RL, Mansbach RS, Shelton KL, Nicholson KL, Grech DM, Wiley JL, Li H, Weber E (1995). Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav Pharmacol 6:577-589.
9. Baron SP, Woods JH (1995). Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons: CGS 19755 and phencyclidine. Psychopharmacology 118:42-51.
10. Benvenga MJ, Wing AV, Del Vecchio RA (1991). The discriminative stimulus effect of MK-801 in ketamine-trained rats. Pharmacol Biochem Behav 38:211-213.
11. 2+ channels in rat cultured cortical neurons. Eur J Pharmacol 257:297-301.
12. Bliss TV, Collingridge GL (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361:31-39.
13. 2B subunit in dorsal horn. Neuropharmacology 38:611-623.
14. Brady KT, Balster RL (1982). Discriminative stimulus properties of ketamine stereoisomers in phencyclidine-trained rats. Pharmacol Biochem Behav 17:291-295.
15. 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J Med Chem 34:3085-3090.
16. Colpaert FC (1999). Drug discrimination in neurobiology. Pharmacol Biochem Behav 64:337-345.
17. Danysz W, Essmann U, Bresink I, Wilke R (1994). Glutamate antagonists have different effects on spontaneous locomotor activity in rats. Pharmacol Biochem Behav 48:111-118.
18. Davis M, Mendelow AD, Perry RH, Chambers IR, James OFW (1995). Stroke and neuroprotection in the aging rat brain. Stroke 26:1072-1078.
19. Depoortere R, Perrault Gh, Sanger DJ (1999). Prepulse inhibition of the startle reflex in rats: effects of compounds acting at various sites on the NMDA receptor complex. Behav Pharmacol 10:51-62.
20. 2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283:1285-1292.
21. Galbicka G, Kautz MA, Jagers T (1994). Behavioral effects of enantiomers of dizocilpine under two "counting" procedures in rats. Pharmacol Biochem Behav 49:943-948.
22. Geter-Douglass B, Witkin JM (1997). Dizocilpine-like discriminative stimulus effects of competitive NMDA receptor antagonists in mice. Psychopharmacology 133:43-50.
23. Geter-Douglass B, Witkin JM (1999). Behavioral effects and anticonvulsivant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology 146:280-289.
24. Geyer M, Krebs-Thomson K, Braff D, Swerdlow N (2001). Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology 156:117-154.
25. Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz M-P, Kew JNC, Levet-Trafit B, Lorez H-P, Malherbe M-T, Miss M-T, Mutel V, Pinard E, Roever S, Schmitt M, Trube G, Wybrecht R, Wyler R, Kemp JA (2002). Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 302:940-948.
26. Ginski MJ, Witkin JM (1994). Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology 114:573-582.
27. Grant KA, Colombo G, Grant J, Rogawski MA (1996). Dizocilpine-like discriminative stimulus effects of low-affinity uncompetitive NMDA antagonists. Neuropharmacology 35:1709-1719.
28. 2B receptors compared with native receptors in rodent brain membranes. J Neurochem 75:2455-2463.
29. Grotta J, Clark W, Coull B, Pettigrew C, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L (1995). Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Stroke 26:602-605.
30. Holtzman SG (1994). Discriminative stimulus effects of dextromethorphan in the rat. Psychopharmacology 116:249-254.
31. Jackson A, Sanger DJ (1988). Is the discriminative stimulus produced by phencyclidine due to an interaction with N-methyl-D-aspartate receptors? Psychopharmacology 96:87-92.
32. Jarvis B, Figgitt D (2003). Memantine. Drugs Aging 20:465-476.
33. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
34. Kew JNC, Kemp JA (1998). An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 512:17-28.
35. Koek W, Woods JH, Colpaert FC (1990). N-methyl-D-aspartate antagonism and phencyclidine-like activity: a drug discrimination analysis. J Pharmacol Exp Ther 253:1017-1025.
36. Koek W (1999). N-methyl-D-aspartate antagonists and drug discrimination. Pharmacol Biochem Behav 64:275-281.
37. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MBJ, Charney DS (1994). Subanesthesic effects of the noncompetitive NMDA anatgonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
38. 2B (ε2) subunit. Eur J Pharmacol 416:185-195.
39. Matsuda K, Kamiya Y, Matsuda S, Yuzaki M (2002). Cloning and characterization of a novel NMDA receptor subunit NR3B: a dominant subunit that reduces calcium permeability. Mol Brain Res 100:43-52.
40. McAllister KH (1996). The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats. Eur J Pharmacol 314:307-311.
41. 3 receptor. Neuropharmacology 34:621-629.
42. Meldrum BS (1994). The role of glutamate in epilepsy and other CNS disorders. Neurology 44:S14-S23.
43. 1 receptors. Behav brain Res 119:33-40.
44. 2B subunits. J Neurochem 70:2147-2155.
45. Narita M, Yoshizawa K, Nomura M, Aoki K, Suzuki T (2001). Role of the NMDA receptor subunit in the expression of the discriminative stimulus effect induced by ketamine. Eur J Pharmacol 423:41-46.
46. Nicholson KL, Jones HE, Balster RL (1997). Evaluation of the reinforcing and discriminative stimulus effects of the N-methyl-D-aspartate competitive antagonist NPC17742 in rhesus monkeys. Behav Pharmacol 8:396-407.
47. Nicholson KL, Jones HE, Balster RL (1998). Evaluation of the reinforcing and discriminative stimulus properties of the low-affinity N-methyl-D-aspartate channel blocker memantine. Behav Pharmacol 9:231-243.
48. Olney JW, Newcomer JW, Farber NB (1999). NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res 33:523-533.
49. Parsons CG, Danysz W, Quack G (1998). Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11:523-569.
50. Parsons CG, Danysz W, Quack G (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 38:735-767.
51. Rogawski MA (2000). Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability. Amino Acids 19:133-149.
52. Solomon RE, Herling S, Domino EF, Woods JH (1982). Discriminative stimulus effects of N-substitued analogs of phencyclidine in rhesus monkeys. Neuropharmacology 21:1329-1336.
53. Sveinbjornsdottir S, Sander JWAS, Upton D, Thompson PJ, Patsalos PN, Hirt D, Emre M, Lowe DA, Duncan GE (1993). The excitatory amino acid antagonist D-CPP-ene (SDZ EAA-494) in patients with epilepsy. Epilepsy Res 16:165-174.
54. Tricklebank MD, Singh L, Oles RJ, Wong EHF, Iversen SD (1987). A role for receptors of N-methyl-D-aspartic acid in the discriminative stimulus properties of phencycridine. Eur J Pharmacol 141:497-501.
55. Urwyler S, Laurie D, Lowe DA, Meier CL, Müller W (1996). Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists. Pharmacological characterization in vitro. Neuropharmacology 35:643-654.
56. West WB, Lou A, Pechersky K, Chachich ME, Appel JB (2000). Antagonism of a PCP drug discrimination by hallucinogens and rerated drugs. Neuropsychopharmacology 22:618-625.
57. Wiley JL, Balster RL (1994). Effects of competitive and non-competitive N-methyl-D-aspartate (NMDA) antagonists in squirrel monkeys trained to discriminate D-CPPene (SDZ EAA 494) from vehicle. Psychopharmacology 116:266-272.
58. Wiley JL, Li H, Balster RL (1997). Discriminative stimulus effects of site-selective N-methyl-D-aspartate antagonists in NPC 17742-trained rats and squirrel monkeys. Psychopharmacology 132:382-388.
59. Wiley JL, Harvey SA, Balster RL, Nicholson KL (2003). Affinity and specificity of N-methyl-D-aspartate channel blockers affect their ability to disrupt prepulse inhibition of acoustic startle in rats. Psychopharmacology 165:378-385.
60. Willetts J, Balster RL, Leander JD (1991). The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci Special Report 1991:62-67.
61. Witkin JM, Steele TD, Sharpe LG (1997). Effects of strychnine-insensitive glycine receptor ligands in rats discriminating dizocilpine or phencyclidine from saline. J Pharmacol Exp Ther 280:46-52.
62. Wong EHF, Kemp JA, Pnestley T, Knight A, Woodruff G, Iversen L (1986). The anticonvulsivant MK-801 is a potent N-methyl-D-aspadate antagonist. Proc Natl Acad Sci USA 83:7104-7108.
63. Yamakura T, Shimoji K (1999). Subunit- and site-specific pharmacology of the NMDA receptor channel. Prog Neurobiol 59:279-298.